Zhitong Finance App News, Kangenbei (600572.SH) issued an announcement. Recently, Hangzhou Kangenbei Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for two specifications (specifications: 30mg, 60mg) of dapoxetine hydrochloride tablets approved and issued by the State Drug Administration. Dapoxetine hydrochloride tablets are short-acting selective serotonin reuptake inhibitors. They are clinically suitable for the treatment of male premature ejaculation (PE) patients aged 18 to 64. They have the characteristics of rapid absorption, rapid efficacy, short half-life, etc., and are safe and well tolerated. The drug has been approved as a chemical in class 4, which is considered to have passed the generic drug consistency evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.